A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-?, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma

A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-?, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma

Publication date: Mar 14, 2019

This is an open-label, multicenter, Phase Ib study to evaluate the safety and therapeutic activity of RO6874281 in combination with pembrolizumab. The study will consist of 2 parts: a safety run-in (Part I) and an expansion (Part II). Part II will start once all participants in Part I have completed the observation period.

Concepts Keywords
Biomarker Medicine
Biopsies Clinical medicine
Biopsy Metastasis
BRAF Chemotherapy
Cardiovascular BRAF
Chemotherapy Breakthrough therapy
Cooperative Group Merck
Hematological Pembrolizumab
Hoffmann La Roche Radiation therapy
Inhibitor Melanoma
Interleukin 2 Antineoplastic drugs
Lesion Cancer treatments
Liver Chemotherapy
Melanoma Radiotherapy
Metastatic Criteria solid tumors
Mutation Archival tumor
Pharmacodynamic Melanoma
Physician Baseline tumor
Radiotherapy
Renal
Tumor

Semantics

Type Source Name
gene UNIPROT ALG3
gene UNIPROT NR4A2
disease MESH renal
disease MESH tumors
gene UNIPROT BRAF
disease DOID mucosal melanoma
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma
gene UNIPROT PDCD1
gene UNIPROT RPL17
drug DRUGBANK Pembrolizumab

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *